Anti-CD19-CAR CMV-specific T-lymphocytes cell therapy (City Of Hope National Medical Center)

N/A

Report date: 2026/04/28 20:00:22

Base Information

Drug NameAnti-CD19-CAR CMV-specific T-lymphocytes cell therapy (City Of Hope National Medical Center)
Drug Alias NameN/A
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionAnti-CD19T lymphocyte replacements
TargetsB-lymphocyte antigen CD19
Therapy Area/IndicationsLymphoma, Mantle-CellLymphoma, Large B-Cell, DiffuseLymphoma, B-Cell +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesCity Of Hope National Medical Center
China Registration ClassN/A

Develop Information

Active CompaniesCity Of Hope National Medical Center
Inactive CompaniesN/A
Active IndicationsLymphoma, Mantle-CellLymphoma, Large B-Cell, DiffuseLymphoma, B-Cell +[5] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A